FDA Reorganization Adds "Directorate" Layer, But Sharpens Agency's Focus
By
Sue Sutter, M. Nielsen Hobbs / Email the Authors / “The Pink Sheet” Jul. 18, 2011, Vol. 73, No. 29
FDA / Word Count: 1795 / Article # 00110718007
Executive Summary
Commissioner Margaret Hamburg’s structural reorganization of FDA leaves the current leadership of the drug and biologic review centers intact but adds a new layer of management and accountability between the medical product center directors and the commissioner’s office.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.